BETA-BLOCKERS DISCONTINUATION AFTER MYOCARDIAL INFARCTION REFERRING TO EJECTION FRACTION
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5994Keywords:
Beta-blockers, Myocardial Infarction, Ejection Fraction, Secondary Prevention, Discontinuation, Cardiovascular OutcomesAbstract
The clinical role of beta-blocker therapy after myocardial infarction (MI) has been debated extensively as the landscape of post-MI management has evolved. Historically, beta-blockers were established as a cornerstone of secondary prevention following landmark randomized controlled trials conducted in the 1980s (Hjalmarson, 1997) that demonstrated significant reductions in all-cause and cardiovascular mortality. However, those foundational studies were conducted before the widespread adoption of primary percutaneous coronary intervention, dual antiplatelet therapy, high-intensity statins, and renin-angiotensin-aldosterone system inhibitors, and they predominantly enrolled patients with reduced left ventricular ejection fraction (LVEF). This review comprehensively synthesizes evidence from contemporary randomized controlled trials including REDUCE-AMI (Yndigegn et al., 2024), ABYSS (Silvain et al., 2024), REBOOT-CNIC (Ibanez et al., 2025), BETAMI-DANBLOCK (Munkhaugen et al., 2025), and landmark individual patient data meta-analysis published between 2024 and 2025, that re-examine the benefits of beta-blockers stratified by LVEF. Findings uniformly demonstrate that among post-MI patients with preserved LVEF (≥50%), long-term beta-blocker therapy does not reduce death or recurrent MI. Patients with mildly reduced LVEF (40-49%) may derive modest benefit, while those with reduced LVEF (<40%) retain a clear and unambiguous indication for beta-blockade. Emerging evidence challenges the appropriateness of routine beta-blocker discontinuation and supports a personalized, ejection fraction-stratified approach. The review also evaluates guideline evolution, mechanisms of action, safety considerations, and directions for future research.
References
A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. (1982). JAMA, 247(12), 1707–1714. https://doi.org/10.1001/jama.1982.03320370021023
Bangalore, S., Makani, H., Radford, M., Thakur, K., Toklu, B., Katz, S. D., DiNicolantonio, J. J., Devereaux, P. J., Alexander, K. P., Wetterslev, J., & Messerli, F. H. (2014). Clinical outcomes with β-blockers for myocardial infarction: A meta-analysis of randomized trials. The American Journal of Medicine, 127(10), 939–953. https://doi.org/10.1016/j.amjmed.2014.05.032
Dargie, H. J. (2001). Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet (London, England), 357(9266), 1385–1390. https://doi.org/10.1016/s0140-6736(00)04560-8
Eichhorn, E. J., & Bristow, M. R. (2001). The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Current Controlled Trials in Cardiovascular Medicine, 2(1), 20–23. https://doi.org/10.1186/cvm-2-1-020
Hjalmarson, A. (1997). Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. The American Journal of Cardiology, 80(9B), 35J-39J. https://doi.org/10.1016/s0002-9149(97)00837-0
Hjalmarson, A., Herlitz, J., Holmberg, S., Rydén, L., Swedberg, K., Vedin, A., Waagstein, F., Waldenström, A., Waldenström, J., Wedel, H., Wilhelmsen, L., & Wilhelmsson, C. (1983). The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation, 67(6 Pt 2), I26-32.
Holt, A., Blanche, P., Zareini, B., Rajan, D., El-Sheikh, M., Schjerning, A.-M., Schou, M., Torp-Pedersen, C., McGettigan, P., Gislason, G. H., & Lamberts, M. (2021). Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: A Danish, nationwide cohort study. European Heart Journal, 42(9), 907–914. https://doi.org/10.1093/eurheartj/ehaa1058
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., Hindricks, G., Kastrati, A., Lenzen, M. J., Prescott, E., Roffi, M., Valgimigli, M., Varenhorst, C., Vranckx, P., Widimský, P., & ESC Scientific Document Group. (2018). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 39(2), 119–177. https://doi.org/10.1093/eurheartj/ehx393
Ibanez, B., Latini, R., Rossello, X., Dominguez-Rodriguez, A., Fernández-Vazquez, F., Pelizzoni, V., Sánchez, P. L., Anguita, M., Barrabés, J. A., Raposeiras-Roubín, S., Pocock, S., Escalera, N., Staszewsky, L., Pérez-García, C. N., Díez-Villanueva, P., Pérez-Rivera, J.-A., Prada-Delgado, O., Owen, R., Pizarro, G., … REBOOT-CNIC Investigators. (2025). Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. The New England Journal of Medicine, 393(19), 1889–1900. https://doi.org/10.1056/NEJMoa2504735
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., … Peer Review Committee Members. (2024). 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 149(1), e1–e156. https://doi.org/10.1161/CIR.0000000000001193
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., Espinola-Klein, C., Fauchier, L., Halle, M., Herrington, W. G., Kautzky-Willer, A., Lambrinou, E., Lesiak, M., Lettino, M., McGuire, D. K., … ESC Scientific Document Group. (2023). 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. European Heart Journal, 44(39), 4043–4140. https://doi.org/10.1093/eurheartj/ehad192
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., Hanssen, H., Harris, J., Lauder, L., McManus, R. J., Molloy, G. J., Rahimi, K., Regitz-Zagrosek, V., Rossi, G. P., Sandset, E. C., … ESC Scientific Document Group. (2024). 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal, 45(38), 3912–4018. https://doi.org/10.1093/eurheartj/ehae178
Munkhaugen, J., Kristensen, A. M. D., Halvorsen, S., Holmager, T., Olsen, M. H., Bakken, A., Sehested, T. S. G., Ruddox, V., Mæng, M., Vikenes, K., Jensen, S. E., Steigen, T., Lambrechtsen, J., Jortveit, J., Bovin, A., Schirmer, H., Christiansen, M. K., Wiseth, R., Mikkelsen, D., … BETAMI–DANBLOCK Investigators. (2025). Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. The New England Journal of Medicine, 393(19), 1901–1911. https://doi.org/10.1056/NEJMoa2505985
Pedersen, T. R. (1983). The Norwegian Multicenter Study of Timolol after Myocardial Infarction. Circulation, 67(6 Pt 2), I49-53.
Rossello, X., Dominguez-Rodriguez, A., Latini, R., Sánchez, P. L., Raposeiras-Roubín, S., Anguita, M., Barrabés, J. A., Grigis, G., Owen, R., Pocock, S., Gómez-Talavera, S., García-Lunar, I., Escalera, N., Pérez-García, C. N., Di Fusco, S. A., Pizarro, G., López Benito, M., Pongetti, G., Rincón-Díaz, L. M., … Ibanez, B. (2026). Beta-blockers after myocardial infarction: Effects according to sex in the REBOOT trial. European Heart Journal, 47(6), 701–715. https://doi.org/10.1093/eurheartj/ehaf673
Rossello, X., Prescott, E. I. B., Kristensen, A. M. D., Latini, R., Fuster, V., Fagerland, M. W., Pocock, S. J., Halvorsen, S., Dominguez-Rodriguez, A., Holmager, T. L. F., Sanchez, P. L., Bakken, A., Raposeiras-Roubin, S., Jensen, S. E., Kimura, T., Ottani, F., Lambrechtsen, J., Anguita, M., Ozasa, N., … Munkhaugen, J. (2025). β blockers after myocardial infarction with mildly reduced ejection fraction: An individual patient data meta-analysis of randomised controlled trials. Lancet (London, England), 406(10508), 1128–1137. https://doi.org/10.1016/S0140-6736(25)01592-2
Silvain, J., Cayla, G., Ferrari, E., Range, G., Puymirat, E., Delarche, N., Guedeney, P., Cuisset, T., Ivanes, F., Lhermusier, T., Petroni, T., Lemesle, G., Bresoles, F., Labeque, J.-N., Pommier, T., Dillinger, J.-G., Leclercq, F., Boccara, F., Lim, P., … ABYSS Investigators of the ACTION Study Group. (2024). Beta-Blocker Interruption or Continuation after Myocardial Infarction. The New England Journal of Medicine, 391(14), 1277–1286. https://doi.org/10.1056/NEJMoa2404204
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. (1999). Lancet (London, England), 353(9146), 9–13.
Wikstrand, J. (2000). MERIT-HF--description of the trial. Basic Research in Cardiology, 95 Suppl 1, I90-7. https://doi.org/10.1007/s003950070016
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., Carter, J., Cohen, J. B., Collins, K. J., Commodore-Mensah, Y., Davis, L. L., Egan, B., Khan, S. S., Lloyd-Jones, D. M., … Williamson, J. D. (2025). 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979), 82(10), e212–e316. https://doi.org/10.1161/HYP.0000000000000249
Yang, W., Sun, X., Zhang, Y., Lu, Z., Shu, Z., & Zhang, K. (2025). β-blocker and clinical outcomes in patients after myocardial infarction: A systematic review and meta-analysis. European Journal of Clinical Pharmacology, 81(12), 1807–1817. https://doi.org/10.1007/s00228-025-03919-2
Yndigegn, T., Lindahl, B., Mars, K., Alfredsson, J., Benatar, J., Brandin, L., Erlinge, D., Hallen, O., Held, C., Hjalmarsson, P., Johansson, P., Karlström, P., Kellerth, T., Marandi, T., Ravn-Fischer, A., Sundström, J., Östlund, O., Hofmann, R., Jernberg, T., & REDUCE-AMI Investigators. (2024). Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. The New England Journal of Medicine, 390(15), 1372–1381. https://doi.org/10.1056/NEJMoa2401479
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Krzysztof Machnik, Beata Tekieli, Wojciech Krzysztof Cyran, Tatsiana Matsiusheuskaya, Weronika Cionżyńska, Bartosz Gaweł, Anna Justkowska-Gebauer, Maksymilian Olesiński, Ewelina Chudyba, Michał Górecki, Dominik Zając
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
